Pfiz­er shares the ADC da­ta that con­vinced it to start a Phase 3 lung can­cer tri­al

When Pfiz­er laid out the am­bi­tious vi­sion for its new on­col­o­gy di­vi­sion in Feb­ru­ary, it an­nounced that it was tak­ing the an­ti­body-drug con­ju­gate sigvotatug ve­dotin …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER